Geron Corporation (GERN)
Geron Corporation
919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 141
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1.36M | N/A | 1951 |
| Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 827.01k | N/A | 1964 |
| Mr. Scott Samuels | Executive VP, Chief Legal Officer & Corporate Secretary | 485.32k | N/A | N/A |
| Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/A | N/A | N/A |
| Ms. Shannon Odam | Senior VP & Chief People Officer | N/A | N/A | 1975 |
| Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753.22k | N/A | 1964 |
| Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/A | N/A | 1962 |
| Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/A | N/A | 1983 |
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Corporate governance
Geron Corporation’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 9; Compensation: 6.
